GLAXOSMITHKLINE PLC Form 6-K April 11, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 11 April 2019

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')		
Transaction notification		
1. Details of PDMR/person closely associated with them ('PCA')		
a) Name	Ms E Walmsley	
b) Position/status	Chief Executive Officer	
c) Initial notification/ amendment	Initial notification	
2. Details of the issuer, emission alloware platform, auctioneer or auction moni	~ ~	
a) Name	GlaxoSmithKline plc	
b) LEI	5493000HZTVUYLO1D793	
Details of the transaction(s): section	to be repeated for (i) each type of	
3. instrument; (ii) each type of transacti	on; (iii) each date; and (iv) each	
place where transaction(s) has been a	conducted	
	Ordinary shares of 25 pence each ('Ordinary Shares')	
a) Description of thefinancial instrume	nt ISIN: GB0009252882	
	Acquisition of Ordinary Shares	

b) Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.	
c) Price(s) and volume(s)	Price(s)Volume(s)£15.91938 (partnership shares)£15.91938 (matching shares)	
Aggregated information		
d) Aggregated volume Price	16 Ordinary Shares 15.9193	
e) Date of the transaction	2019-04-09	

- f) Place of the transaction London Stock Exchange (XLON)
- 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr R G Connor b) Position/status President, Global Vaccines Initial notification/ c) Initial notification amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793
- Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
- place where transaction(s) has been conducted

a)	Description of thefinancial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c)	Price(s) and volume(s) Aggregated information	Price(s)Volume(s)£15.91938 (partnership shares)£15.91938 (matching shares)
d)	Aggregated volume Price	16 Ordinary Shares £15.9193
e) f)	Date of the transaction Place of the transaction	2019-04-09 London Stock Exchange (XLON)

1.	Details of PDMR/person closely associ	ated with them ('PCA')	
a)	Name	Mr S Dingemans	
b)	Position/status	Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction		
۷.	platform, auctioneer or auction monitor	•	
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to	be repeated for (i) each type of	
3.	instrument; (ii) each type of transaction		
	place where transaction(s) has been con	nducted	
a)	Description of thefinancial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.	
c)	Price(s) and volume(s)	Price(s)Volume(s)£15.91938 (partnership shares)£15.91938 (matching shares)	
	Aggregated information		
d)	Aggregated volume Price	16 Ordinary Shares £15.9193	
e)	Date of thetransaction	2019-04-09	

f)	Place of the transaction	London Stock Exchange (XLON)	
	Details of PDMR/person closely associ		
a)	Name	Ms S Jackson	
b)	Position/status	SVP, Global Communications and CEO Office	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowand		
	platform, auctioneer or auction monitor		
	Name	GlaxoSmithKline plc	
D)	LEI Details of the transaction(s): section to	5493000HZTVUYLO1D793 be repeated for (i) each type of	
3.	Details of the transaction(s): section to be repeated for (i) each type of . instrument; (ii) each type of transaction; (iii) each date; and (iv) each		
	place where transaction(s) has been cor		
a)	Description of thefinancial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.	
c)	Price(s) and volume(s)	Price(s)Volume(s)£15.91938 (partnership shares)£15.91938 (matching shares)	
	Aggregated information		
d)	Aggregated volume Price	16 Ordinary Shares £15.9193	
e)	Date of thetransaction	2019-04-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr D Jackson
		PCA of Ms S Jackson (SVP,
b)	Position/status	Global Communications and CEO
		Office)
()	Initial notification/	Initial notification
c)	amendment	Initial notification
\mathbf{r}	Details of the issuer, emission allowand	ce market participant, auction
Ζ.	platform, auctioneer or auction monitor	r
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted Ordinary shares of 25 pence each

a) Description of thefinancial instrument ('Ordinary Shares') ISIN: GB0009252882

b) Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s)Volume(s)£15.91938 (partnership shares)£15.91938 (matching shares)
Aggregated information	
d) Aggregated volume Price	16 Ordinary Shares £15.9193
e) Date of thetransaction	2019-04-09
f) Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Mr N Hirons	
b)	Position/status	SVP, Global Ethics and	
	Initial matification (Compliance	
c)	Initial notification/ amendment	Initial notification	
2	Details of the issuer, emission allowand	ce market participant, auction	
2.	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to	be repeated for (i) each type of	
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each		
	place where transaction(s) has been conducted		
	1	Ordinary shares of 25 pence each	
	T	('Ordinary Shares')	
a)	Description of thefinancial instrument	•	
	*	ISIN: GB0009252882	
		ISIN: GB0009252882	
		Acquisition of Ordinary Shares	
b)	Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share	
b)		Acquisition of Ordinary Shares	
b)		Acquisition of Ordinary Shares under the Company's Share Reward Plan.	
	Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan. Price(s) Volume(s)	
		Acquisition of Ordinary Shares under the Company's Share Reward Plan. Price(s) Volume(s) £15.9193 8 (partnership shares)	
c)	Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan. Price(s) Volume(s)	

Aggregated volume	16 Ordinary Shares
Price	£15.9193
e) Date of thetransactionPlace of the transactionf)	2019-04-09 London Stock Exchange (XLON)

1	Details of DDMD/nervor algority access	at a d social the same ('DC'A ')	
1. a)	Details of PDMR/person closely associ Name	Mr D S Redfern	
,	Position/status	Chief Strategy Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
	LEI	5493000HZTVUYLO1D793	
,	Details of the transaction(s): section to	be repeated for (i) each type of	
3.	instrument; (ii) each type of transaction place where transaction(s) has been cor		
a)	Description of thefinancial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share	
		Reward Plan.	
c)	Price(s) and volume(s)	Reward Plan.Price(s)Volume(s)£15.91938 (partnership shares)£15.91938 (matching shares)	
c)	Price(s) and volume(s) Aggregated information	Price(s) Volume(s) £15.9193 8 (partnership shares)	
c) d)		Price(s) Volume(s) £15.9193 8 (partnership shares)	
·	Aggregated information Aggregated volume	Price(s) Volume(s) £15.9193 8 (partnership shares) £15.9193 8 (matching shares) 16 Ordinary Shares	

- 1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr R Simard
 b) Position/status President, Pharma Supply Chain
 c) Initial notification/ amendment Initial notification
 c) Details of the issuer, emission allowance market participant, auction
- ². platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc

		-			
b)	LEI	5493000HZTVUYLO1D793			
	Details of the transaction(s): section to be repeated for (i) each type of				
3.	. instrument; (ii) each type of transaction; (iii) each date; and (iv) each				
с.	place where transaction(s) has been conducted				
	place where transaction(s) has been con	Ordinary shares of 25 pence each			
		-	-		
a)	Description of thefinancial instrument	('Ordinary Shares')			
<i>a)</i>		ISIN: GB0	0009252882		
		Acquisitio	n of Ordinary Shares		
	Nature of thetransaction	-	-		
b)		under the Company's Share Reward Plan.			
		Reward Pl	an.		
		Price(s)	Volume(s)		
c)	Price(s) and volume(s)	£15.9193	8 (partnership shares)		
		£15.9193	8 (matching shares)		
	Aggregated information				
d)		16 Ordina	ry Shares		
u)	Aggregated volume	16 Ordinary Shares			
	Price	£15.9193			
e)	Date of thetransaction	2019-04-0	9		
£	Place of the transaction	Landan Ci	a als Establisher and (VLON)		
f)		London Stock Exchange (XLON)			

1.	. Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Ms C Tho	mas
b)	Position/status	SVP, Hun	nan Resources
c)	Initial notification/ amendment	Initial noti	fication
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmi	thKline plc
b)	LEI	5493000H	ZTVUYLO1D793
3.	Details of the transaction(s): section to instrument; (ii) each type of transaction place where transaction(s) has been con	; (iii) each	
a)	Description of thefinancial instrument	('Ordinary	shares of 25 pence each Shares') 0009252882
b)	Nature of thetransaction		n of Ordinary Shares Company's Share an.
c)	Price(s) and volume(s)	£15.9193	Volume(s) 8 (partnership shares) 8 (matching shares)
d)	Aggregated information		

Aggregated volume Price	16 Ordinary Shares £15.9193
e) Date of thetransaction	2019-04-09
f) Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associ	ated with them ('PCA')		
	Name	Mr P C Thomson		
b)	Position/status	President, Global Affairs		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction			
۷.	platform, auctioneer or auction monitor			
a)	Name	GlaxoSmithKline plc		
b)	LEI	5493000HZTVUYLO1D793		
	Details of the transaction(s): section to be repeated for (i) each type of			
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each			
	place where transaction(s) has been conducted			
		Ordinary shares of 25 pence each		
	T	('Ordinary Shares')		
a)	Description of thefinancial instrument	ISIN: GB0009252882		
b)	Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.		
		$\mathbf{Driss}(\mathbf{a}) = \mathbf{Valuma}(\mathbf{a})$		
(\mathbf{a})	Price(s) and volume(s)	Price(s)Volume(s)£15.91937 (partnership shares)		
0)	Filee(s) and volume(s)	£15.9193 7 (participating shares)		
	Aggregated information	£15.9195 7 (matching shares)		
	Aggregated information			
d)	Aggregated volume			
u)	Aggiegated volume	14 Ondinamy Change		
	00 0	14 Ordinary Shares		
	Price	£15.9193		
ല	Price	£15.9193		
e)	00 0	•		

- 1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mrs V A Whyte
- b) Position/status Company Secretary Initial notification/
- c) amendment Initial notification
- 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc

,	LEI Details of the transaction(s): section to	5493000HZTVUYLO1D793 be repeated for (i) each type of		
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of thefinancial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882		
b)	Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.		
c)	Price(s) and volume(s) Aggregated information	£15.9193	Volume(s) 8 (partnership shares) 8 (matching shares)	
d)	Aggregated volume Price	16 Ordinary Shares £15.9193		
e) f)	Date of the transaction Place of the transaction	2019-04-09 London Stock Exchange (XLON)		

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: April 11, 2019

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc